title: Evidence for nucleotide excision repair as a modifying factor of O6-methylguanine-DNA methyltransferase-mediated innate chloroethylnitrosourea resistance in human tumor cell lines.
abstract: We examined the O6-methylguanine-DNA methyltransferase (MGMT) protein as well as MGMT activity levels and the excision repair cross-complementing rodent repair deficiency gene, ERCC2 (XPD), protein levels in 14 human tumor cell lines not selected for chloroethylnitrosourea (CENU) resistance. These results were compared with 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) cytotoxicity and UV light sensitivity. MGMT protein correlated significantly with MGMT activity (r = 0.9497, p = 0.0001). There was no significant linear correlation between BCNU cytotoxicity and MGMT content as determined by both Western analysis (r = 0.139, p = 0. 6348) and activity assay (r = 0.131, p = 0.6515). However, MGMT-rich cell lines were found to be more resistant than MGMT-poor cell lines to BCNU (t = 2.2375, p = 0.0225) but not to UV (t = 1.1734, p = 0.1317). Furthermore, the most BCNU-sensitive cell lines were all MGMT-poor. UV sensitivity was significantly correlated to BCNU cytotoxicity (r = 0.858, p = 0.0001). Significant correlations were found between ERCC2 protein levels and BCNU cytotoxicity (r = 0.786, p = 0.0009) or UV sensitivity (r = 0.874, p = 0.0001). Our results confirm that MGMT plays an important role in CENU resistance, but not in UV resistance. The correlation of UV sensitivity with BCNU cytotoxicity suggests that nucleotide excision repair is an important modifying factor of MGMT-mediated innate CENU resistance in human tumor cell lines, especially in highly resistant cell lines. ERCC2 may be implicated in this process.
authors.affiliation: Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, 3755 Côte Ste. Catherine, Montreal, Quebec, Canada H3T 1E2.
authors.forename: Z P
authors.initials: ZP
authors.lastname: Chen
authors.forename: A
authors.initials: A
authors.lastname: Malapetsa
authors.forename: A
authors.initials: A
authors.lastname: McQuillan
authors.forename: D
authors.initials: D
authors.lastname: Marcantonio
authors.forename: V
authors.initials: V
authors.lastname: Bello
authors.forename: G
authors.initials: G
authors.lastname: Mohr
authors.forename: J
authors.initials: J
authors.lastname: Remack
authors.forename: T P
authors.initials: TP
authors.lastname: Brent
authors.forename: L C
authors.initials: LC
authors.lastname: Panasci
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D015153:Blotting, Western; D002330:Carmustine / Q000494:pharmacology*; D002452:Cell Count / Q000187:drug effects; D004265:DNA Helicases; D004260:DNA Repair / Q000235:genetics*; D004268:DNA-Binding Proteins; D006801:Humans; D019853:O(6)-Methylguanine-DNA Methyltransferase / Q000187:drug effects / Q000235:genetics*; D011506:Proteins / Q000235:genetics* / Q000378:metabolism; D014157:Transcription Factors; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000528:radiation effects; D014466:Ultraviolet Rays; D051759:Xeroderma Pigmentosum Group D Protein
chemical_list: D018906:Antineoplastic Agents, Alkylating; D004268:DNA-Binding Proteins; D011506:Proteins; D014157:Transcription Factors; D019853:O(6)-Methylguanine-DNA Methyltransferase; D004265:DNA Helicases; D051759:Xeroderma Pigmentosum Group D Protein; C497292:ERCC2 protein, human; D002330:Carmustine